Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.59 |
| ▸ | CCR5 | P51681 | 1/20 | 0.59 |
| ▸ | CCR8 | P51685 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9963463 | 0.81 | CCR1 (0.41) | CCR1CCR5CCR8KMT2AMEN1 | |
| SCHEMBL1088410 | 0.74 | CCR1 (1.00) | CCR1CCR5CCR8KMT2AMEN1 | |
| SCHEMBL1717340 | 0.72 | CCR1 (0.53) | CCR1CCR5CCR8KMT2AMEN1 | |
| SCHEMBL22135835 | 0.70 | CCR1 (0.50) | CCR1CCR5CCR8KMT2AMEN1 | |
| SCHEMBL18980487 | 0.70 | CCR1 (0.45) | CCR1CCR5CCR8KMT2AMEN1 | |
| SCHEMBL97051 | 0.70 | CISD1 (0.50) | CCR1CCR5CCR8KMT2AMEN1 | |
| SCHEMBL29216607 | 0.70 | CCR1 (0.55) | CCR1CCR5CCR8KMT2AMEN1 | |
| SCHEMBL1716704 | 0.70 | CCR1 (0.55) | CCR1CCR5CCR8KMT2AMEN1 | |
| SCHEMBL3156710 | 0.69 | CCR1 (0.33) | CCR1CCR5CCR8ADORA2A | |
| SCHEMBL4796219 | 0.68 | CCR1 (0.54) | CCR1CCR5CCR8KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709483-A1 | NEW 5H-PYRROLO[3,2-B:5,4-C']DIPYRIDINE DERIVATIVES AND 6,7,8,9-TETRAHYDRO-5H-PYRROLO[3,2-B:5,4-C']DIPYRIDINE USEFUL IN THE TREATMENT OF CANCER | Institut Regional du Cancer de Montpellier (FR) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024235836-A1 | NEW 5H-PYRROLO[3,2-B:5,4-C']DIPYRIDINE DERIVATIVES AND 6,7,8,9-TETRAHYDRO-5H-PYRROLO[3,2-B:5,4-C']DIPYRIDINE USEFUL IN THE TREATMENT OF CANCER | INSTITUT REGIONAL DU CANCER DE MONTPELLIER (FR) | 2024-11-21 | — | — | WO | disclosed |
| EP-4461368-A1 | 5H-PYRROLO[3,2-B:5,4-C']DIPYRIDINE DERIVATIVES AND 6,7,8,9-TETRAHYDRO-5H-PYRROLO[3,2-B:5,4-C']DIPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Institut Regional du Cancer de Montpellier (FR) | 2024-11-13 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-2152712-B1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER (US) | 2012-01-11 | — | — | EP | disclosed |
| US-7964607-B2 | Pyrazolo[3,4-d]pyrimidine compounds | PFIZER INC. (US) | 2011-06-21 | — | — | US | disclosed |
| EP-2152712-A1 | AMINO-HETEROCYCLIC COMPOUNDS | Pfizer Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20090030003-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC | 2009-01-29 | — | — | US | disclosed |
| WO-2008139293-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030003-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PDE9A, PDE2A, PDE10A | CCR1 3080/4885CCR5 2010/4885CCR8 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.